NEW
YORK, July 21, 2023 /PRNewswire/
-- Jakubowitz Law announces that an investigation into
potential securities fraud allegations has commenced
on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ:
TNDM)
To be contacted by a member of our team, fill out the
form:
https://claimyourloss.com/securities/tandem-class-action-loss-submission-form/?id=42396&from=4
Further details on the investigation: The investigation
focuses on whether Tandem issued false and/or misleading statements
and/or failed to disclose information pertinent to
investors. After the market closed on November 2, 2022, Tandem released its third
quarter 2022 results. The Company held a conference call on the
same day to discuss its third quarter 2022 financial and operating
results. Tandem substantially lowered its guidance for the year
during the call. In response to the earnings news, market analysts
downgraded Tandem and its stock price fell $14.57 per share, from $51.34 per share on November 2, 2022 to close at $36.77 per share on November 3, 2022.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities
fraud. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/tndm-fraud-alert-jakubowitz-law-is-investigating-tandem-diabetes-care-inc-in-connection-with-potential-violations-of-federal-securities-laws-301882544.html
SOURCE Jakubowitz Law